Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351-1359)

Venkatesh Pradeep

首页> 外文期刊>Ophthalmology >Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351-1359)

【24h】

Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351-1359)

机译：Re：Wells等人：AfliBercept，Bevacizumab或Ranibizumab用于糖尿病黄斑水肿：两年的比较有效性随机临床试验（眼科。2016; 123：1351-1359）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Ophthalmology》 |2017年第4期|共3页
作者
Venkatesh Pradeep;
展开▼
作者单位

All India Inst Med Sci Dr Rajendra Prasad Ctr Ophthalm Sci Dis Retina Vitreous &

Uvea New Delhi;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
专利

1. Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351-1359) [J] . Venkatesh Pradeep Ophthalmology . 2017,第4期

机译：Re：Wells等人：AfliBercept，Bevacizumab或Ranibizumab用于糖尿病黄斑水肿：两年的比较有效性随机临床试验（眼科。2016; 123：1351-1359）
2. Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359) REPLY [J] . Wells John A., Glassman Adam R., Ayala Allison R., Ophthalmology . 2017,第1期

机译：Re：Wells等人：AfliBercept，Bevacizumab或Ranibizumab用于糖尿病黄斑水肿：对比疗效随机临床试验的两年结果（2016年眼科; 123：1351-1359）回复
3. Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1358) [J] . Tornambe Paul Ophthalmology . 2017,第3期

机译：Re：Wells等人：AfliBercept，Bevacizumab或Ranibizumab用于糖尿病黄斑水肿：两年的比较有效性随机临床试验（2016年眼科; 123：1351-1358）
4. COMPARISON OF CLINICAL EFFECTIVENESS OF LASER ACUPUNCTURE AND AMITRYTALINE IN DIABETIC PERIPHERAL NEUROPATHY (DPN) A SHAM CONTROLED RANDOMIZED CLINICAL TRIAL [C] . Imran Hassan Khan, Shahzad Anwar, Asif Hanif, Mechanisms for low-light therapy IX . 2014

机译：激光控制与阿米替林在糖尿病周围神经病变（DPN）控制的随机临床试验中的临床疗效比较
5. Aflibercept Bevacizumab or Ranibizumab for Diabetic Macular Edema: Two-year Results from a Comparative Effectiveness Randomized Clinical Trial [O] . John A. Wells, Adam R. Glassman, Allison R. Ayala, -1

机译：AfliberceptBevacizumab或Ranibizumab治疗糖尿病性黄斑水肿：两年疗效比较随机临床试验结果
6. Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359) [O] . Mahesh P. Shanmugam, Kaustubh B. Harshey, Rajesh Ramanjulu, 2017

机译：Re：Wells等人：AfliBercept，Bevacizumab或Ranibizumab用于糖尿病黄斑水肿：对比有效性随机临床试验的两年结果（2016年眼科; 123：1351-1359）

Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351-1359)

著录项

相似文献

相关主题

期刊订阅